Theralytix was founded by entrepreneur and real estate investment speaker Matthew McClellan. Matthew was watching in horror as his friend's daughter, who has cystic fibrosis, was dying from a lung infection called Pseudomonas aeruginosa. People with cystic fibrosis have a genetic defect that causes their immune system to fight off Pseudomonas aeruginosa or its close relative Burkholderia cepacia. These species are highly destructive to lung tissue and can cause rapid loss of lung capacity in these patients. Antibiotics begin to fail once biofilms take hold in the lungs; children can succumb to the infections at a very young age.
While frantically searching for a treatment for Mary, through Mary's mother, Matthew came across information about phage therapy. Shocked that this was not available for the U.S. market as well as the global need for this type of therapy, it was worth a try. Matthew contacted one of the Eastern European clinics and, after testing for sensitivity, acquired some of the product. There was a dramatic result: within hours after using phages Mary's face returned to its normal color and she began to breathe normally. Within a couple of weeks, the infection was gone.
Accessing the product was, however, quite difficult. Produced in Eastern Europe under questionable conditions, it was necessary to follow bureaucratic protocol that took several weeks. Since that time, FDA has banned compassionate use import of these products from Eastern Europe, citing non-standard manufacturing methods and medical claims that the products “cure” diseases — where there is no proof of such claims.
“These products need to be readily available to people in the US and elsewhere, not just in Eastern Europe”.